Background A promising approach to the treatment of chronic ischaemic heart disease and
congestive heart failure is the use of stem cells. The last decade has seen a plethora of …

Importance Stem cell therapy is a promising treatment strategy for patients with heart failure,
which accounts for more than 10% of deaths in the United States annually. Despite more …

Heart failure remains a major cause of death and disability, requiring rapid development of
new therapies. Bone marrow-derived mesenchymal stem cell (MSC)-based therapy is an …

Heart failure (HF) is one of the leading causes of death worldwide and has reached
epidemic proportions in most industrialized nations. Despite major improvements in the …

Aim Bone marrow-derived mesenchymal stem cells (BM-MSCs) are the most well-studied
and characterised stem cell types. This review was undertaken of the current available …

This review summarizes the results of clinical trials of cell therapy in patients with heart
failure (HF). In contrast to acute myocardial infarction (where results have been consistently …

Rationale: Cell-based therapies are a promising intervention for the treatment of heart failure
(HF) secondary to ischemic and nonischemic cardiomyopathy. However, the clinical efficacy …

Introduction Ischemic heart diseases, especially the myocardial infarction, is a major hazard
problem to human health. Despite substantial advances in control of risk factors and …

Over the past 2 decades, there have been numerous stem cell studies focused on cardiac
diseases, ranging from proof-of-concept to phase 2 trials. This series of papers focuses on …

Objective To evaluate bone marrow stem cell treatment (BMSC) in patients with ischemic
heart disease (IHD) and no option of revascularization. Background Autologous BMSC …